![FOXO4 (Proxofim) [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/fox.jpg)
$115.00
FOXO4-DRI is an experimental D-retro-inverso peptide studied for its interaction with the FOXO4–p53 pathway and senescent cells. Evidence is limited to laboratory and animal research; human safety and efficacy have not been established. For laboratory research only.
For laboratory research only. Not for human or animal consumption.
VIP Peptides · Research Compound
FOXO4-DRI is an experimental D-retro-inverso peptide studied for
senescent-cell research. Current evidence is preclinical and does not
establish safety or efficacy in humans.
Product Information
FOXO4-DRI is a synthetic peptide designed using a D-retro-inverso
structure. It has been studied as a senolytic research compound—a
compound investigated for its potential to affect senescent cells.
In preclinical models, FOXO4-DRI was studied for its ability to
interfere with the interaction between FOXO4 and p53. Researchers
proposed that this could allow p53-related apoptosis pathways to
become active in senescent cells.
The D-retro-inverso design was intended to increase resistance to
enzymatic breakdown. This design feature does not establish how the
peptide behaves or how safe it would be in people.
| Product | FOXO4-DRI |
|---|---|
| Alternate name | Proxofim |
| Peptide length | 43 amino acids |
| Design | D-retro-inverso (DRI) |
| Interaction studied | FOXO4–p53 |
| Product form / quantity | Confirm against the product label |
Research Areas
Cell and animal studies have examined whether disrupting the
FOXO4–p53 interaction can affect senescent-cell survival and
apoptosis pathways. Selective effects in preclinical models do not
show that healthy tissues would be spared in people.
In aged-mouse models, researchers reported changes in measures
including fur density, kidney function markers, physical activity,
and fitness. These are animal findings, not demonstrated human
benefits.
Preclinical research has also explored Leydig-cell and testosterone
markers, lung-fibrosis models, vascular markers, and chemotherapy-
related effects. These findings require further study and do not
establish clinical uses.
No human clinical trials of FOXO4-DRI were identified. Human safety,
effective dosing, long-term outcomes, and efficacy remain unknown.
Cell studies involving human cells are laboratory research, not
clinical trials in people.
Evidence Overview
The research so far primarily involves cell studies and animal models.
Results such as changes in kidney markers, activity, tissue fibrosis,
or reproductive markers cannot be assumed to predict outcomes in
people.
Safety, efficacy, appropriate administration, and long-term effects
in humans have not been established. Research results do not support
anti-aging or disease-treatment claims for this product.
Safety & Regulatory Status
There is no established human safety database for FOXO4-DRI. Limited
reports from uncontrolled community use cannot determine safety or
predict how an individual may respond. Theoretical effects of removing
senescent cells also remain under investigation.
FOXO4-DRI is not FDA-approved for any indication. Product identity,
purity, and quality may vary between research suppliers.
Age & Policy Confirmation
Please confirm your age and review the policies before entering.
![Cagrilintide [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/cagrilitinde-300x300.jpg)
![SNAP-8 (Acetyl Octapeptide-3) [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/snap8-300x300.jpg)
![BPC-157 [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/bpc-300x300.jpg)
![GLP2T [60mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/glp2t-300x300.jpg)
Reviews
There are no reviews yet.